Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School
University of Kentucky
Grupo Espanol de Tumores Neuroendocrinos
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Milton S. Hershey Medical Center
University of Texas Southwestern Medical Center
EMD Serono
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Janssen Pharmaceutical K.K.
University of California, San Diego
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Mayo Clinic
MacroGenics
National Cancer Institute (NCI)
Yale University
Merck Sharp & Dohme LLC
Flamingo Therapeutics NV
University of California, Davis
Dana-Farber Cancer Institute
Emory University
University of Michigan Rogel Cancer Center
Takeda
Royal Marsden NHS Foundation Trust
Boehringer Ingelheim
Radiation Therapy Oncology Group
Boehringer Ingelheim
University of Pittsburgh
Emory University
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Memorial Sloan Kettering Cancer Center
I-Mab Biopharma US Limited
University of Texas Southwestern Medical Center
University of California, San Francisco
University of Colorado, Denver